Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study

Background & Aims: Pretreatment predictors of finite nucleo(s)tide analogue (NUC) therapy remain elusive. We studied the association between pretreatment HBV DNA levels and outcomes after therapy cessation. Methods: Patients with chronic hepatitis B who were HBeAg negative at the start of NU...

Full description

Bibliographic Details
Main Authors: Milan J. Sonneveld, Shao-Ming Chiu, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Bömmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:JHEP Reports
Subjects:
HBV DNA
HBsAg
HBcrAg
HBsAg loss
Entecavir
Tenofovir
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555923001210

Internet

http://www.sciencedirect.com/science/article/pii/S2589555923001210

Similar Items